Traditional antidepressant therapy (ADT) is the mainstay of treatment. Despite the availability of various ADTs, as many as 50% to 60% of patients do not respond to ADT. Aripiprazole (Abilify) is an atypical antipsychotic (AAP) and is the only drug approved by Health Canada for the adjunctive treatment of MDD in adults who had an inadequate
Darolutamide Plus ADT Shows Efficacy and Safety Vs ADT Alone in mHSPC The advent of drugs targeting specific genetic mutations, such as
In the TITAN trial, treatment with apalutamide plus ADT was compared with ADT plus placebo. drugs.4-6. Overall, the incidence of common
Despite the ARASENS trial establishing the efficacy of ARPI, ADT, and chemotherapy, it was only compared with ADT plus docetaxel, and
In 6-week, fixed-dose trials the incidences within the recommended doses (VRAYLAR 1.5 mg/day antidepressant therapy [ADT] or 3 mg/day ADT vs placebo ADT)
Investigators found that the combination of ADT plus enzalutamide reduced the risk of metastasis or death by 58% over ADT alone. They found that
ADT alone, ADT plus docetaxel, and ADT plus abiraterone, Dreicer said.
Investigators found that the combination of ADT plus enzalutamide reduced the risk of metastasis or death by 58% over ADT alone. They found that
Traditional antidepressant therapy (ADT) is the mainstay of treatment. Despite the availability of various ADTs, as many as 50% to 60% of patients do not respond to ADT. Aripiprazole (Abilify) is an atypical antipsychotic (AAP) and is the only drug approved by Health Canada for the adjunctive treatment of MDD in adults who had an inadequate
Comments